Arrhythmia Clinical Trial
Official title:
Serratus Anterior Plane Block or Erector Spinae Plane Block Used as an Adjuvant for Hybrid Arrhythmia Ablation Surgery
The purpose of this study is to evaluate differences between single-shot EQUAL ropivacaine doses of the serratus anterior plane block (SAPB) or erector spinae plane block (ESPB) injection, when used as adjuvant to treat postoperative pain, after one-stage unilateral hybrid arrhythmia (atrial fibrillation, ventricular tachycardia, inappropriate sinus node tachycardia) ablation surgery. The primary outcomes are to evaluate block placement efficacy in the hybrid surgery setting (total time to block placement in seconds, time to visualization of location of injection in seconds, adequacy of ropivacaine spread) by picturing and worst numerical scale pain at rest or moving, using a visual analog pain scale from 0= no pain to 10= maximal pain, in the first 12 hours after admission to the post-anaesthesia care unit. Secondary outcomes aim to evaluate to investigate pain location, additional analgesic consumption and requests, ease of breathing, breathing quality, sleeping quality and quantity, duration of hospitalisation, and general level of satisfaction.
Status | Recruiting |
Enrollment | 132 |
Est. completion date | December 1, 2024 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age 18-80 years. 2. Provision of signed informed consent prior to any study-specific procedure 3. Selected for Hybrid Rhythm ablation surgery (ISNT, VT, AF) 4. American Society of Anesthesiologist physical Status I to III 5. Dutch, French or English speaking 6. Ability to follow the study protocol 7. BMI > 35 kg/m2 . BMI or Body mass index will be obtained from body weight in kg divided by the square of the length in meter and is expressed in kg/m2 - Exclusion Criteria: - a. History of chronic pain or drug treatment abuse - b. Depression, psychiatric morbidity or mal-adaptive coping behaviour - c. Neuropathy - d. Severe anxiety or other mental ailment, taking drugs affecting their capacity to assess pain (gabapentin, pregabalin, opiod use) - e. Chronic or acute skin infection of the back or the lateral thorax - f. Hypersensitivity to ropivacaine - g. Severe hepatic, renal , pulmonary or cardiac (EF < 30%) disease or refuse to participate to the study.. |
Country | Name | City | State |
---|---|---|---|
Belgium | Universitair Ziekenhuis | Brussel |
Lead Sponsor | Collaborator |
---|---|
Universitair Ziekenhuis Brussel |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | evaluate block placement efficacy in the hybrid surgery setting specifically time to placement in seconds | Time to placement in seconds | Time to placement: 1200 seconds | |
Primary | evaluate block placement efficacy in the hybrid surgery setting visualization time of location of injection by picturing | visualisation time of location of injection | Visualisation is done by picturing to confirm adequate block (up 120 seconds) | |
Primary | evaluate block placement efficacy in the hybrid surgery setting adequacy of ropivacaine spread by picturing | Block placement efficacy by seeing the ropivacaine spread | picturing Confirms time of block placement (up to 300 seconds) | |
Primary | Worst numerical scale pain in the first 12 h after admission to the post-anaesthesia care unit. | Maximal pain assesed by visual analog scale ,where 0= no pain 10= maximal pain | 12 hours | |
Secondary | Pain location | Place of pain: sternal; back, thorax, shoulder, throat, neck | 72 hours | |
Secondary | Additional analgesic consumption and requests | Pain drugs used: paracetamol in grams, piritramide in milligrams, diclofenac in milligrams, aspirin in milligrams, colchicine in grams | 72 hours | |
Secondary | Ease of breathing, breathing quality | Breathing evaluation: superficial, tense, normal, deep | 72 hours | |
Secondary | Sleeping quantity | Number of hours slept after surgery | 72 hours | |
Secondary | Duration hospital Stay | Length of hospital stay | From 2 to 15 days | |
Secondary | Body Mass Index | BMI or Body mass index is obtained from body weight in kg divided by the square of the length in meter) and is expressed in kg/m2).Exclusion criteria if above > 35 kg/m2 | Will be assessed on screening day or exported up to 2 weeks before screening day. | |
Secondary | Ideal body weight | Ideal body weight will be calculated from body weight in kg, length in cm and gender on https://by globalrph.com/medcalc. It is expressed in kg and used for drug dosing | Will be assessed on screening day or exported up to 2 weeks before screening day. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05048602 -
Drug-induced Brugada Syndrome Research Database
|
||
Completed |
NCT05053243 -
Clinical Validation of the AliveCor Kardia 12L and 6L Devices
|
N/A | |
Completed |
NCT01913561 -
The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT01396226 -
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
|
Phase 2 | |
Terminated |
NCT00721149 -
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
|
Phase 3 | |
Completed |
NCT00756886 -
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
|
N/A | |
Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
Completed |
NCT00510029 -
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
|
Phase 1 | |
Completed |
NCT00578617 -
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
|
N/A | |
Active, not recruiting |
NCT00135174 -
Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study
|
N/A | |
Completed |
NCT00119847 -
Electrophysiological Effects of Late PCI After MI
|
N/A | |
Completed |
NCT00035490 -
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT01076361 -
Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
|
N/A | |
Completed |
NCT00004560 -
Public Access Defibrillation (PAD) Community Trial
|
Phase 3 | |
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT01076348 -
Model 4965 Post-Approval Study
|
||
Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 |